Inventor
LUNDBERG ANTE SVEN
US17 patents
⚠️ This page may combine multiple inventors who share the name “LUNDBERG ANTE SVEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CRISPR THERAPEUTICS AG
10 patentsUS11559588B2Jan 24, 2023
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
CRISPR THERAPEUTICS AG12 citations83
US11866727B2Jan 9, 2024
Materials and methods for treatment of glycogen storage disease type 1A
CRISPR THERAPEUTICS AG4 citations67
US11174469B2Nov 16, 2021
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
CRISPR THERAPEUTICS AG1 citations60
US12186406B2Jan 7, 2025
Materials and methods for treatment of hereditary haemochromatosis
CRISPR THERAPEUTICS AG0 citations59
US11083799B2Aug 10, 2021
Materials and methods for treatment of hereditary haemochromatosis
CRISPR THERAPEUTICS AG1 citations59
US11920148B2Mar 5, 2024
Compositions and methods for gene editing
CRISPR THERAPEUTICS AG0 citations57
US11564997B2Jan 31, 2023
Materials and methods for treatment of friedreich ataxia and other related disorders
CRISPR THERAPEUTICS AG0 citations50
US11407997B2Aug 9, 2022
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
CRISPR THERAPEUTICS AG0 citations50
US12043843B2Jul 23, 2024
Materials and methods for treatment of hemoglobinopathies
CRISPR THERAPEUTICS AG0 citations42
US11851653B2Dec 26, 2023
Materials and methods for treatment of alpha-1 antitrypsin deficiency
CRISPR THERAPEUTICS AG0 citations42
VERTEX PHARMA
7 patentsUS11459587B2Oct 4, 2022
Materials and methods for treatment of pain related disorders
VERTEX PHARMA3 citations71
US12442020B2Oct 14, 2025
Materials and methods for treatment of pain related disorders
VERTEX PHARMA0 citations60
US11427838B2Aug 30, 2022
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
VERTEX PHARMA1 citations60
US12053531B2Aug 6, 2024
Materials and methods for treatment of Duchenne Muscular Dystrophy
VERTEX PHARMA0 citations56
US11369692B2Jun 28, 2022
Materials and methods for treatment of Duchenne Muscular Dystrophy
VERTEX PHARMA1 citations56
US12161674B2Dec 10, 2024
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
VERTEX PHARMA0 citations53
US11801313B2Oct 31, 2023
Materials and methods for treatment of pain related disorders
VERTEX PHARMA0 citations50